A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - Rationale and design [ISRCTN55725285]

Current Controlled Trials in Cardiovascular Medicine

Volumn 5, Issue , 2004, Pages

  Pater, Cornel ^a   Bhatnagar, Deepak ^b   Berrou, Jean Pascal ^a   Luszick, Joachim ^a   Beckmann, Katrin ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

^b ROYAL OLDHAM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPROSARTAN; HYDROCHLOROTHIAZIDE; MOXONIDINE; RAMIPRIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HEART PROTECTION; HUMAN; INDIVIDUALIZATION; LOW DRUG DOSE; METABOLIC REGULATION; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SIDE EFFECT;

EID: 27544451146     PISSN: 14686694     EISSN: 14686694     Source Type: Journal    
DOI: 10.1186/1468-6708-5-9     Document Type: Article

References (87)

1. Bella JN, Devereux RB, Roman MJ: Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (The Strong Heart Study). Am J Cardiol 2001, 87:1260-1265.
2. Palmieri V, Bella JN, Arnett DK: Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects. Hypertension Genetic Epidemiology Network (HyperGEN) Study. Circulation 2001, 103:102-107.
3. Tomiyama H, Kimura Y, Okazaki R: Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension 2000, 36:245-249.
4. Deedwania PC: Hypertension and diabetes. New therapeutic options. Arch Intern Med 2000, 160:1585-1594.
5. Cooper ME, Johnston CI: Optimizing treatment of hypertension in patients with diabetes. JAMA 2000, 283:3177-3179.
6. Laakso M: Benefits of strict glucose and blood pressure control in type 2 diabetes. Lessons from the UK Prospective Diabetes Study. Circulation 1999, 99:461-462.
7. Yki-Järvinen H: Management of type 2 diabetes mellitus and cardiovascular risk. Lessons from intervention trials. Drugs 2000, 60:975-983.
8. Mancia G: Presentation of the ESH-ESC Guidelines for management of arterial hypertension. Program and abstracts of the 13th European Meeting on Hypertension. Milan, Italy. June 13-17, 2003
9. Guidelines Committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053 [http://www.eshonline.org/documents/2003_guidelines.pdf].
10. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
11. Guidelines Subcommittee: 1999 WHO-International Society of Hypertension, Guidelines for the management of hypertension. J Hypertens 1999, 17:151-183.
12. American Diabetes Association: Standards of medical care for patients with diabetes mellitus. Diabetes Care 2001, 24(suppl 1):S33-S43.
13. Hansson L, Zanchetti A, Carmuthers SG, Dahloef B, Elmfeldt D, Julius S: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755-1762.
14. American Diabetes Association 2002: Standards of ethical care for patients with diabetes mellitus. Diabetes Care 2002, 25(suppl 1):S33-49.
15. Chobanian AV, Bakris GL, Black HR, The national High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289:2560-3572.
16. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2003, 26(suppl 1):S80-S82.
17. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(suppl 1):S1-S266.
18. Adler AI, Stratton IM, Neil HA. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
19. United Kingdom Prospective Diabetes Group: Tight blood pressure control and risk of macrovascular and microvasrulcar complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
20. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134-147.
21. Elliot WJ, Weir DR, Black HR: Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 2000, 160:1277-1283.
22. UK Prospective Diabetes Study Group: Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998, 317:720-726.
23. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH: Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
24. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001, 345:851-860.
25. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1967, 202:1028-1034.
26. Veterans Administration Cooperative Study Group on antihypertensive Agents: Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970, 213:1143-1152.
27. PROGRESS Collaborative Study Group: Randomized trial of Perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041.
28. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
29. Shen D-C, Shieh S-M, Fuh M: Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988, 66:580-583.
30. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2:419-423.
31. Jarret RJ, Keen H, McCartney M: Glucose tolerance and blood pressure in two population samples: their relation to diabetes mellitus and hypertension. Int J Epidemiol 1978, 7:15-24.
32. Lucas CP, Estigarribia JA, Darga LL: Insulin and blood pressure in obesity. Hypertension 1985, 7:702-706.
33. Modan M, Halkin H, Almog S: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985, 75:809-817.
34. Ferrannini E, Buzzigoli G, Bonadona R: Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
35. Shen D-C, Shieh S-M, Fuh M: Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988, 66:580-583.
36. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989, 2:419-423.
37. Fuller JH, Shipley MJ, Rose G: Coronary heart disease and impaired glucose tolerance: the Whitehall Study. Lancet 1980, 1:1373-1376.
38. Pyörälä K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2:131-141.
39. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773-2776.
40. Laws A, Reaven GM: Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 1992, 231:25-30.
41. Shieh S-M, Shen M, Fuh MM-T: Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension. Atherosclerosis 1987, 67:49-55.
42. Fuh M-T, Shieh SM, Wu D-A: Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 1987, 147:1031-1038.
43. Lip GYH, Blann AD, Zarifis J: Soluble adhesion P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report. J Hypertens 1995, 13:1674-1678.
44. Desouza CA, Dengel DR, Macko RF: Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997, 10:1335-1341.
45. Hasslacher C, Sted W, Wahl P, Ritz E: Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1985, 28:6-11.
46. Knuiman MW, Welborn TA, McCann VJ, Stanton KG, Constable IJ: Prevalence of diabetic complications in relation to risk factors. Diabetes 1986, 35:1332-1339.
47. Kannel WB: An overview of risk in cardiovascular disease. In Prevention of Coronary Disease, Practical Management of Risk Factors Edited by: Kaplan, Neward, Stanler. Philadelphia, WB Sanders:69-83.
48. UK Prospective Diabetes Study (UKPDS) Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
49. Curb JD, Pressel SL, Cutler JA: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996, 276:1886-1892.
50. Tuomilehto J, Rastenyte D, Birkenhager WH: Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial investigators. N Engl J Med 1999, 340:677-684.
51. Hansson L, Zanchetti A, Carruthers SG: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:1755-1762.
52. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(suppl 2):B54-B64.
53. Fuller J, Stevens LK, Chaturvedi N, Holloway JE: Antihypertensive therapy in diabetes mellitus (Cochrane Review). The Cochrane Library Issue 4 Oxford: Update Software; 1998.
54. Kaplan NM: Treatment of Hypertension: Drug therapy. In Clinical Hypertension 7th edition. Baltimore, MD, Williams and Wilkins; 1998:181-265.
55. Zanchetti A, Ruilope LM: Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002, 20:2099-2110.
56. Unger T: Neurohomonal modulation in cardiovascular disease. Am Heart J 2000, 139:S2-S8.
57. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis, Ann Intern Med 1993, 118:129-138.
58. Ruggeneti P, Perna A, Ghererdi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril. REIN Follow-up Trial. Lancet 1998, 352:1252-1256.
59. Zuanetti G, Latini R, Maggioni AP: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction-data from GISSI-3 Study. Circulation 1997, 96:4239-4245.
60. Tatti P, Pahor M, Byington RP: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998, 21:597-603.
61. Yusuf S, Sleght P, Pogue J: Effects of angiotensin-enzyme-converting inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
62. Heart Outcomes Prevention Evaluation Study Investigators: Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and MICRO-HOPE Substudy. Lancet 2000, 355:253-259.
63. Lonn EM, Yusuf S, Dzavik V: Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE). Circulation 2001, 103:919-925.
64. Physician's Desk Reference. 55th edition. Montvale, NJ: Medical Economics Company, Inc; 2001:654-566. 996-998, 1902-1904, 2166-2168
65. Paran E, Anson O, Neuman L: The effects of replacing beta-blockers with an angiotensin-converting enzyme inhibitor on the quality of life of hypertensive patients. Am J Hypertens 1996, 9:1206-1213.
66. Sebastian JL, McKinney WP, Kaufman J: Anglotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient clinic population. Chest 1991, 99:36-39.
67. Moore MA, Edelman JM, Gazdick LP: Choice of initial antihypertensive medication may influence the extent to which patients stay on therapy: a community-based study of losartan-based regimen vs. usual care. High Blood Press 1998, 7:156-167.
68. Vidal JLL, Vicente VL, Roca JA: Sexual dysfunction in hypertensivepatients treated with losartan. Am J Med Sci 2001, 321:336-341.
69. Phelps KR, Lieberman RL, Oh MS: Pathophysiology of the syndrome of hyporeninemic hypoaldosteronism. Metabolism 1980, 29:186-199.
70. Curb JD, Pressel SL, Cutler JA: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension. JAMA 1996, 276:1886-1892.
71. Borhani NO, Mercuri M, Borhani PA: Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 1996, 276:785-791.
72. The ALLHAT Officers and Coordinators for the ALLHAT Colaborative Research Group: Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981-2997.
73. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlortalidone: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 283:2981-2975.
74. Lakshman MR, Reda DJ, Materson BJ: Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999, 159(6):551-558.
75. Weir MR, Moser M: Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000, 139:174-183.
76. Moser M: Lipid abnormalities and diuretics. Am Fam Physician 1989, 40:213-220.
77. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
78. Neal B, MacMahon S, Chapman N: for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955-1964.
79. Gradman AH, Acevedo C: Evolving strategies for the use of combination therapy in hypertension, Curr Hypertens Rep 2002, 4(5):343-349.
80. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
81. Curb JD, Pressel MS, Cutler JA: Effect of diuretic-based hypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996, 276:1886-1892.
82. Chrisp P, Faulds D: Maxonidine A review of its pharmacology, and therapeutic use in essential hypertension. Drugs 1992, 44:993-1012.
83. Kaan EC, Brückner R, Frohly P, Tulp M, Shafer SG, Ziegler D: Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995, 5(suppl 1):19-27.
84. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulcer NR, Russel GI, Thom S, Williams B: Better blood pressure control: how to combine drugs. Journal of Human Hypertension 2003, 17:81-86.
85. Ramsay LE: British Hypertension Society guidelines for hypertension management 1999. BMJ 1999, 319:630-635.
86. Chalmers J: 1999 World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Sub-committee. Clin Exp Hypertens 1999, 21:1009-1060.
87. Epstein M, Bakris G: Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996, 156:1969-1978.